These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17635375)

  • 1. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt.
    Everson GT; Martucci MA; Shiffman ML; Sterling RK; Morgan TR; Hoefs JC;
    Aliment Pharmacol Ther; 2007 Aug; 26(3):401-10. PubMed ID: 17635375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial.
    Everson GT; Shiffman ML; Morgan TR; Hoefs JC; Sterling RK; Wagner DA; Kulig CC; Curto TM; Wright EC;
    Aliment Pharmacol Ther; 2008 May; 27(9):798-809. PubMed ID: 18266997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.
    Burton JR; Helmke S; Lauriski S; Kittelson J; Everson GT
    Transl Res; 2021 Jul; 233():5-15. PubMed ID: 33400995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.
    Everson GT; Shiffman ML; Hoefs JC; Morgan TR; Sterling RK; Wagner DA; Desanto JL; Curto TM; Wright EC;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):589-601. PubMed ID: 19053983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma glucagon concentration in cirrhosis is related to liver function but not to portal-systemic shunting, systemic vascular resistance, or urinary sodium excretion.
    Lewis FW; Adair O; Hossack KF; Everson GT; White JC; Rector WG
    J Lab Clin Med; 1991 Jan; 117(1):67-75. PubMed ID: 1987311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis.
    Koeda N; Iwai M; Kato A; Suzuki K
    Aliment Pharmacol Ther; 2005 Apr; 21(7):851-9. PubMed ID: 15801920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis.
    Lemoine M; Katsahian S; Ziol M; Nahon P; Ganne-Carrie N; Kazemi F; Grando-Lemaire V; Trinchet JC; Beaugrand M
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1102-10. PubMed ID: 18691352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C.
    Dinesen L; Caspary WF; Chapman RW; Dietrich CF; Sarrazin C; Braden B
    Dig Liver Dis; 2008 Sep; 40(9):743-8. PubMed ID: 18339592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?
    Cheung RC; Currie S; Shen H; Bini EJ; Ho SB; Anand BS; Hu KQ; Wright TL; Morgan TR;
    J Clin Gastroenterol; 2008 Aug; 42(7):827-34. PubMed ID: 18285716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The results of porto-systemic shunting in patients with liver cirrhosis].
    Nazyrov FG; Deviatov AV; Ibadov RA; Khashimov ShKh
    Khirurgiia (Mosk); 2008; (10):32-5. PubMed ID: 19008812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test.
    McRae MP; Kittelson J; Helmke SM; Everson GT
    Clin Transl Sci; 2024 Apr; 17(4):e13786. PubMed ID: 38558534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of hepatitis C: non-invasive fibrosis markers and/or liver biopsy.
    Bedossa P
    Liver Int; 2009 Jan; 29 Suppl 1():19-22. PubMed ID: 19207962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of portosystemic shunt by summation of radioactivity during 201thallium chloride portal scintigraphy in patients with chronic liver disease.
    Kato H; Kaito M; Gabazza EC; Ikoma J; Iwasa M; Nakamura K; Watanabe S; Adachi Y
    Hepatogastroenterology; 2000; 47(33):672-7. PubMed ID: 10919009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus.
    Kumar M; Kumar A; Hissar S; Jain P; Rastogi A; Kumar D; Sakhuja P; Sarin SK
    Liver Int; 2008 May; 28(5):690-8. PubMed ID: 18433395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
    Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
    Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation.
    Toniutto P; Fabris C; Bitetto D; Falleti E; Avellini C; Rossi E; Smirne C; Minisini R; Pirisi M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1904-8. PubMed ID: 17914968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C.
    Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A
    Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.